Cited by 99Cancer-related Molecular PathwaysAntioxidant Activity and Oxidative StressGrowth Hormone and Insulin-like Growth Factors

Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1

Nahum, Amit, Zeller, Lior, Danilenko, Michael, Prall, Owen W. J., Watts, Colin K. W., Sutherland, Robert L., Levy, Joseph, Sharoni, Yoav·2006·European Journal of Nutrition

Abstract

Background Insulin-like growth factors (IGFs) play an important role in normal and cancerous cell proliferation. Moreover, in recent studies IGF-I has been implicated as a major cancer risk factor. The tomato carotenoid lycopene and all-trans retinoic acid (atRA) have been shown to inhibit growth factor-induced proliferation of different types of cancer cells. This action is associated with inhibition of cell cycle progression in G0/G1 phase. Cyclin D1 acts as a growth factor sensor in G1 phase and is overexpressed in many breast cancer tumors. We have previously demonstrated that slowdown of serum-stimulated cell cycle progression from G1 to S phase by lycopene correlates with reduction in cyclin D1 levels, suggesting that the expression of this protein is a main target for lycopene's action.Aim of the study To determine whether the reported reduction in cyclin D1 level is the key mechanism for lycopene and atRA inhibitory action on IGF-I-induced cell cycle progression.Results Human breast (MCF-7) and endometrial (ECC-1) cancer cells were synchronized in G0/G1 phase by serum deprivation followed by stimulation with IGF-I. Cell treatment with lycopene and atRA inhibited IGF-I-stimulated cell cycle progression from G1 to S phase and decreased retinoblastoma protein (pRb) phosphorylation. These events were associated with a reduction in cyclin D1 and p21(CIP1/WAF1) level, but not that of p27(KIP1). To test the hypothesis that the decrease in cyclin D1 has a major role in the inhibitory effects of lycopene and atRA, we examined the ability of these two agents to suppress cell cycle progression in MCF-7.7D1.13 cells which are capable of expressing cyclin D1 under the control of the Zn-inducible metallothionein promoter. Our results showed that ectopic expression of cyclin D1 can overcome cell cycle inhibition caused by lycopene and atRA.Conclusions Our findings suggest that attenuation of cyclin Dl levels by lycopene and atRA is an important mechanism for the reduction of the mitogenic action of IGF-I.

Integrity signals

Registry

Crossref · 10.1007/s00394-006-0595-x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Growth inhibition of lycopene on MCF-7 breast cancer cells is associated with decreased G1-S cell cycle progression, decreased cyclin D1 expression, and stabilization of p27 in the cyclin E-CDK complex.

    “It has been reported that the growth inhibition of lycopene on MCF-7 breast cancer cells was also associated with decreased G1-S cell cycle progression, decreased cyclin D1 expression, and stabilization of p27 in the cyclin E-CDK complex [7, 66].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nahum, A., Zeller, L., Danilenko, M., Prall, O. W. J., Watts, C. K. W., Sutherland, R. L., Levy, J., & Sharoni, Y.
Affiliations
  • Ben-Gurion University of the Negev (IL)
  • Garvan Institute of Medical Research (AU)
Corresponding author
Levy, Joseph
Venue
European Journal of Nutrition
Published
2006-03-24
Volume
45
Issue
5
Pages
275-282
ISSN
  • 1436-6207 (ISSN-L)
  • 1436-6215
OpenAlex
W1969071751
Cited by
99
References
33
Citations by year
2026: 5 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 8 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 4 · 2015: 7 · 2014: 3 · 2013: 7 · 2012: 6
FWCI
3.65
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Nutrition (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Israel Academy of Sciences and Humanities
  • Israel Science Foundation
  • Division of Electrical, Communications and Cyber Systems
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
lycopene, insulin-like growth factor I, cyclin D1, all-trans retinoic acid, cell cycle progression, G1/S transition, retinoblastoma protein phosphorylation, p21, breast cancer cells, endometrial cancer cells, tomato carotenoids, cancer cell proliferation inhibition
MeSH terms
Lycopene, Antineoplastic Agents, Breast Neoplasms, Carotenoids, Cell Cycle, Cell Division, Female, Humans, Insulin-Like Growth Factor I, Phosphorylation, Time Factors, Tretinoin, Tumor Cells, Cultured, Blotting, Western, Endometrial Neoplasms, Culture Media, Serum-Free, Cyclin D1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review